Point72 Middle East FZE »

Revance Therapeutics shares owned by Point72 Middle East FZE

Quarter-by-quarter ownership of Revance Therapeutics (RVNC) shares owned by Point72 Middle East FZE from 13F filings

Historical chart of Point72 Middle East FZE investment in Revance Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Revance Therapeutics held by Point72 Middle East FZE consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Revance Therapeutics by Point72 Middle East FZE

Quarter filed Position value Share count Share price at filing
2023-12-31 $653k 74k 8.79
2023-09-30 $24k 2.1k 11.47
2023-06-30 $854k 34k 25.31
2022-12-31 $149k 8.0k 18.46

More positions owned by Point72 Middle East FZE

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Spdr Dow Jones Indl Average Ut Ser 1 Call Option (DIA)
General Motors Company (GM)
Eli Lilly & Co. (LLY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Caterpillar Call Option (CAT)
UnitedHealth (UNH)
Amazon (AMZN)
Jd.com Spon Adr Cl A (JD)
Lauder Estee Cos Cl A Call Option (EL)
Target Corporation Call Option (TGT)
At&t (T)
Analog Devices Call Option (ADI)
Synopsys (SNPS)

View all positions for Point72 Middle East FZE

Top funds holding Revance Therapeutics

Palo Alto Investors
Vanguard Group
Franklin Resources
Jpmorgan Chase & Co
Jennison Associates
Bamco
Walleye Trading Advisors
Goldman Sachs Group
Rice Hall James & Associates
Charles Schwab Investment Management
Citadel Advisors
Wellington Management Company
D. E. Shaw & Co
HighTower Advisors
Balyasny Asset Management

View all funds holding Revance Therapeutics